Allakos Inc

NASDAQ ALLK

Download Data

Allakos Inc Net Debt to EBITDA Ratio 2 year CAGR for the quarter ending March 31, 2024

Allakos Inc Net Debt to EBITDA Ratio 2 year CAGR is NA for the quarter ending March 31, 2024. The net debt to EBITDA ratio measures the level of a company's net debt relative to its earnings before interest, taxes, depreciation, and amortization (EBITDA). It is calculated by dividing the net debt (total debt minus cash and cash equivalents) by EBITDA. This ratio provides insights into the company's ability to repay its debt using its operating earnings. A higher ratio indicates a higher level of debt relative to earnings, suggesting potential financial risk and difficulty in debt repayment. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Allakos Inc Net Debt to EBITDA Ratio for the quarter ending March 31, 2023 was 1.16, a 1,599.06% change year over year.
  • Allakos Inc Net Debt to EBITDA Ratio for the quarter ending March 31, 2022 was -0.08, a -103.43% change year over year.
  • Allakos Inc Net Debt to EBITDA Ratio for the quarter ending March 31, 2021 was 2.26, a -47.81% change year over year.
  • Allakos Inc Net Debt to EBITDA Ratio for the quarter ending March 31, 2020 was 4.33, a 182.79% change year over year.
NASDAQ: ALLK

Allakos Inc

CEO Dr. Robert Alexander Ph.D.
IPO Date July 19, 2018
Location United States
Headquarters 975 Island Drive, Redwood City, CA, United States, 94065
Employees 131
Sector Healthcare
Industry Biotechnology
Description

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Similar companies

DAWN

Day One Biopharmaceuticals Inc

NA

NA

CRBU

Caribou Biosciences Inc

NA

NA

KURA

Kura Oncology Inc

NA

NA

NXTC

NextCure  Inc

NA

NA

GTHX

G1 Therapeutics Inc

NA

NA

HRTX

Heron Therapeuti

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email